Back

Impact of aortic regurgitation on long-term outcomes in heart failure with preserved ejection fraction

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Heart failure with preserved ejection fraction (HFpEF) 2 Heart Failure with Preserved Ejection Fraction (HFpEF) ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Cristina De Colle

Cardiovascular Research Center Aalst, Aalst (Belgium)

8 More presentations in this session

Presentation thumbnail
Usefulness of right ventricular longitudinal systolic strain to predict the progression to heart failure with preserved ejection fraction in hypertensive patients.
Doctor M. Marketou (Heraklion, GR)
Abstract Slides
Presentation thumbnail
Impact of atrial flow regulator implantation on survival in patients with heart failure with reduced and preserved ejection fraction: a post-hoc analysis of the PRELIEVE study
Doctor L. Lauder (Basel, CH)
Abstract Slides
Presentation thumbnail
Is pulmonary artery wedge pressure a reliable surrogate of left ventricular end-diastolic pressure during exercise for diagnosing HFpEF in patients with unexplained dyspnea?
Assistant Professor S. Caravita (Bergamo, IT)
Abstract Slides
Presentation thumbnail
Clinical trajectory and outcomes of patients with heart failure with preserved ejection fraction with normal or indeterminate diastolic function
Doctor B. Oeun (Suita, JP)
Abstract Slides
Presentation thumbnail
Insight into the relationship between heart rate and mortality in patients in sinus rhythm with heart failure with preserved ejection fraction
Doctor Y. Nakagawa (Kawanishi, JP)
Abstract Slides

Access the full session

Session thumbnail
Heart failure with preserved ejection fraction (HFpEF) 2

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
Distinguishing heart failure with reduced ejection fraction from heart failure with preserved ejection fraction: a phenomics approach.
thumbnail
Congress Presentation
Pharmacotherapy in HFpEF: where do cardiometabolic drugs fit in?
thumbnail
Congress Session
Clinical phenotypes of heart failure with preserved ejection fraction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources